Health Stocks in Motion
Updated from 3:45 p.m.
Shares of Vivus (VVUS) were among the best-performing health-related stocks Thursday, rising 18.3% after the company announced positive results from its phase II study of Avanafil, the company's experimental impotence drug.
The drug, which was well tolerated and showed no serious adverse events, did particularly well at the 300-milligram level. "The ability to initiate intercourse in 30 minutes, which is half the time as compared to the recommended initiation time of two of the currently approved PDE5 inhibitors, while maintaining a high degree of efficacy, should help differentiate Avanafil and give men a meaningful option to treat their ED," one of the investigators in the study said. The study covered 284 patients who were treated with placebo or Avanfil at various doses for 12 weeks. Shares traded up 61 cents to $3.95.
Applied Biosystems (ABI) fell 1.5% after the company said it would cut about 250 jobs in its research and development, marketing and operations areas. Applied expects to take a pretax charge during the fourth quarter of between $20 million and $22 million, which will cover severance costs and the closing of facilities. "These adjustments are in keeping with our program to enhance Applied Biosystems' performance and should better align our resources with the needs of our customers," the company said. During fiscal 2006, the company expects to add employees in field sales and support, manufacturing quality and advanced research, it said. Shares traded down 32 cents to $20.49.Shares of McKesson (MCK) fell modestly after the company announced a contract extension with the U.K.'s National Health Service. The contract extension, which brings the contract term to 12.75 years, up from 10 years, calls for McKesson to continue providing an electronic staff record system for managing human resources and payroll. McKesson will receive a cash payment of $143 million as part of the new extension, mostly for McKesson's investment in the project to date. Shares traded down 12 cents to $43.47.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV